OBJECTIVE

To determine whether dapagliflozin, which selectively inhibits renal glucose reabsorption, lowers hyperglycemia in patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents (OADs).

RESEARCH DESIGN AND METHODS

This was a randomized, double-blind, three-arm parallel-group, placebo-controlled, 26-center trial (U.S. and Canada). Based on data from an insulin dose-adjustment setting cohort (n = 4), patients in the treatment cohort (n = 71) were randomly assigned 1:1:1 to placebo, 10 mg dapagliflozin, or 20 mg dapagliflozin, plus OAD(s) and 50% of their daily insulin dose. The primary outcome was change from baseline in A1C at week 12 (dapagliflozin vs. placebo, last observation carried forward [LOCF]).

RESULTS

At week 12 (LOCF), the 10- and 20-mg dapagliflozin groups demonstrated −0.70 and −0.78% mean differences in A1C change from baseline versus placebo. In both dapagliflozin groups, 65.2% of patients achieved a decrease from baseline in A1C ≥0.5% versus 15.8% in the placebo group. Mean changes from baseline in fasting plasma glucose (FPG) were +17.8, +2.4, and −9.6 mg/dl (placebo, 10 mg dapagliflozin, and 20 mg dapagliflozin, respectively). Postprandial glucose (PPG) reductions with dapagliflozin also showed dose dependence. Mean changes in total body weight were −1.9, −4.5, and −4.3 kg (placebo, 10 mg dapagliflozin, and 20 mg dapagliflozin). Overall, adverse events were balanced across all groups, although more genital infections occurred in the 20-mg dapagliflozin group than in the placebo group.

CONCLUSIONS

In patients receiving high insulin doses plus insulin sensitizers who had their baseline insulin reduced by 50%, dapagliflozin decreased A1C, produced better FPG and PPG levels, and lowered weight more than placebo.

Treatment of hyperglycemia in patients with type 2 diabetes remains a challenge, particularly in those who require insulin as the disease progresses (1,2). Various combinations of insulin with oral antidiabetic agents (OADs) have been investigated (2,,,,,8). Often, these combination therapies become less effective in controlling hyperglycemia over time, particularly as a result of weight gain and worsening insulin resistance as well as progressive failure of insulin secretion.

Hypoglycemia, weight gain, and subsequent increased insulin resistance are significant factors that limit optimal titration and effectiveness of insulin (2). Weight gain with insulin therapy, used alone or with OADs (7,9), is in part a consequence of reducing glucosuria (10,11). Among commonly used OADs, thiazolidinediones (TZDs) and sulfonylureas intrinsically contribute to weight gain, whereas metformin causes weight loss and dipeptidyl peptidase-4 inhibitors are weight neutral. Overall, there is a need for novel agents that can be safely administered to help achieve glycemic targets without increasing the risks of weight gain or hypoglycemia.

A novel approach to treating hyperglycemia targets receptors for renal glucose reabsorption (12). Agents that selectively block sodium-glucose cotransporter 2 (SGLT2), located in the proximal tubule of the kidney, inhibit glucose reabsorption and induce its elimination through urinary excretion (13). Preclinical models have shown that SGLT2 inhibition lowers blood glucose independently of insulin (14,,17). Dapagliflozin, a highly selective inhibitor of SGLT2, has demonstrated efficacy, alone or in combination with metformin, in reducing hyperglycemia in patients with type 2 diabetes (18,19) but has not been tested in patients requiring insulin. This study was designed to determine whether dapagliflozin is effective in lowering blood glucose in patients with type 2 diabetes who have not responded adequately to insulin combined with oral therapies that act through insulin-dependent mechanisms.

This randomized, single- and double-blind, three-arm parallel-group, placebo-controlled trial was conducted in 26 study centers in the U.S. and Canada. Institutional review boards or independent ethics committees for each center approved the protocol. All patients provided written informed consent. The trial consisted of a 10- to 21-day qualification period, 12-week treatment phase, and 4-week follow-up phase. Starting at day −7, patients were instructed on a diet and exercise program, pursuant to American Diabetes Association or similar local guidelines, to be followed throughout the study. Until day 1, patients maintained their stable dose of OADs and insulin.

We used an adaptive trial design with two cohorts. The purpose of the first cohort was to identify a reduced insulin starting dose unlikely to cause hypoglycemia after addition of dapagliflozin. Four patients received single-blind 20 mg dapagliflozin after having their daily insulin dose decreased by 50%. If at least one patient recorded a glucose value ≤100 mg/dl in this cohort, lesser dose reductions (i.e., 30 or 10%) would not be tested, and the daily insulin dose reduction for patients in the larger second cohort would be set at 50%. This was the case, and in the second treatment cohort, patients were randomly assigned 1:1:1 on day 1 to double-blind placebo, 10 mg dapagliflozin, or 20 mg dapagliflozin once daily, in addition to open-label therapy with 50% of their usual daily insulin dose and their OAD(s).

Patients performed self-monitoring of blood glucose five times daily during the 3–5 days before clinic visits at weeks 1, 2, 4, 6, 8, 10, and 12. No dose modifications of blinded study medication or OAD(s) were allowed during the treatment phase. In patients with or at risk of hypoglycemia, insulin could be down-titrated for self-monitored blood glucose levels <54 mg/dl or mean daily glucose <100 mg/dl or when clinically necessary as determined by the investigator. Patients experiencing major hypoglycemia were discontinued from the study. For any fasting plasma glucose (FPG) level >240 mg/dl at weeks 4 and 6, >220 mg/dl at week 8, or >200 mg/dl at week 10, the insulin dose could be increased after a retest. Patients lacking glycemic control despite up-titration or whose modified insulin dose exceeded baseline were discontinued from the study.

Men and women with type 2 diabetes, aged 18–75 years, with BMI ≤45 kg/m2 and A1C 7.5–10%, were enrolled between October 2006 and November 2007. Patients were receiving stable-dose insulin sensitizer therapy (metformin ≥1,000 mg and/or pioglitazone ≥30 mg or rosiglitazone 4 mg) for ≥6 weeks and insulin therapy for ≥12 weeks before enrollment (insulin dose must have been ≥50 units of U100 daily and stable for ≥6 weeks). Laboratory criteria included fasting C-peptide ≥0.8 ng/ml, serum creatinine <1.5 mg/dl (men) or <1.4 mg/dl (women), and a urine microalbumin-to-creatinine ratio <300 mg/g or, if exceeded on spot check, a 24-h urine total protein <3 g/24 h. Major exclusion criteria were a history of type 1 diabetes, aspartate transaminase and/or alanine transaminase >2.5 times the upper limits of normal, creatine kinase ≥3 times the upper limits of normal, symptoms of severely uncontrolled diabetes, a history of severe hypoglycemia, and unstable condition or serious cardiovascular, renal, or hepatic disease.

Trial outcomes (dapagliflozin vs. placebo)

The primary efficacy measure was change from baseline in A1C at week 12 (last observation carried forward [LOCF]). Secondary efficacy measures at week 12 (LOCF) included changes from baseline in FPG and total daily dose of insulin (TDDI), the proportion of patients achieving a decrease in A1C ≥0.5% from baseline, and the proportion of patients achieving A1C <7%. Tertiary end points included changes from baseline in total body weight and in postprandial glucose (PPG) measured by an oral glucose tolerance test. Safety outcomes were assessed by treatment-emergent adverse events, vital signs, and laboratory measurements, including 24-h urine collections for volume and electrolytes.

Statistical analysis

For the treatment cohort, the sample size target of 22 patients per treatment group was chosen to allow for the calculation of 95% CI for the primary end point with a half-width of 0.42% for each treatment group, assuming a 1% SD; the half-width of a 95% CI for differences between mean treatment changes was estimated to be 0.59%. The primary efficacy dataset consisted of all randomly assigned patients who took ≥1 dose of double-blind study medication. Analyses of efficacy variables (except change from baseline in insulin dose) excluded data after insulin up-titration. Analyses for change from baseline in A1C, FPG, insulin dose, and total body weight at week 12 (LOCF) were performed using an ANCOVA model with treatment group as effect and baseline value as a covariate. No statistical hypothesis testing was planned for this study designed for exploratory analysis.

Patient population

Of 163 patients screened for the treatment cohort, 71 were randomly assigned (Fig. 1). Demographic and baseline characteristics are reported in Table 1.

Figure 1

Patient disposition.

Figure 1

Patient disposition.

Close modal
Table 1

Demographic and baseline characteristics of randomly assigned patients in the treatment cohort

Placebo + insulin10 mg dapagliflozin + insulin20 mg dapagliflozin + insulin
n 23 24 24 
Age (years) 58.4 ± 6.5 55.7 ± 9.2 56.1 ± 10.6 
Sex    
    Male 16 (69.6) 13 (54.2) 13 (54.2) 
    Female 7 (30.4) 11 (45.8) 11 (45.8) 
Race    
    White 22 (95.7) 22 (91.7) 23 (95.8) 
    Black/African American 1 (4.2) 1 (4.2) 
    Asian 1 (4.2) 
    Other 1 (4.3) 
Ethnicity*    
    Hispanic/Latino 5 (21.7) 3 (12.5) 2 (8.3) 
    Non-Hispanic/Latino 12 (52.2) 14 (58.3) 16 (66.7) 
    Not reported 6 (26.1) 7 (29.2) 6 (25.0) 
Weight (kg) 101.8 ± 16.5 103.4 ± 10.2 101.2 ± 15.3 
BMI (kg/m234.8 ± 4.6 35.5 ± 3.6 36.2 ± 4.6 
Duration of type 2 diabetes (years) 13.8 ± 7.3 11.8 ± 5.8 11.3 ± 5.6 
Background antihyperglycemic medication    
    Metformin + insulin 18 (78.3) 19 (79.2) 16 (66.7) 
    Metformin + insulin + TZD 4 (17.4) 2 (8.3) 6 (25.0) 
    TZD + insulin 1 (4.3) 3 (12.5) 2 (8.3) 
Total daily insulin dose 90.0 (70.0–136.0) 93.0 (67.5–136.0) 84.5 (58.0–135.5) 
A1C (%) 8.4 ± 0.9 8.4 ± 0.7 8.5 ± 0.9 
FPG (mg/dl) 165.9 ± 51.5 156.0 ± 39.0 161.6 ± 55.0 
Placebo + insulin10 mg dapagliflozin + insulin20 mg dapagliflozin + insulin
n 23 24 24 
Age (years) 58.4 ± 6.5 55.7 ± 9.2 56.1 ± 10.6 
Sex    
    Male 16 (69.6) 13 (54.2) 13 (54.2) 
    Female 7 (30.4) 11 (45.8) 11 (45.8) 
Race    
    White 22 (95.7) 22 (91.7) 23 (95.8) 
    Black/African American 1 (4.2) 1 (4.2) 
    Asian 1 (4.2) 
    Other 1 (4.3) 
Ethnicity*    
    Hispanic/Latino 5 (21.7) 3 (12.5) 2 (8.3) 
    Non-Hispanic/Latino 12 (52.2) 14 (58.3) 16 (66.7) 
    Not reported 6 (26.1) 7 (29.2) 6 (25.0) 
Weight (kg) 101.8 ± 16.5 103.4 ± 10.2 101.2 ± 15.3 
BMI (kg/m234.8 ± 4.6 35.5 ± 3.6 36.2 ± 4.6 
Duration of type 2 diabetes (years) 13.8 ± 7.3 11.8 ± 5.8 11.3 ± 5.6 
Background antihyperglycemic medication    
    Metformin + insulin 18 (78.3) 19 (79.2) 16 (66.7) 
    Metformin + insulin + TZD 4 (17.4) 2 (8.3) 6 (25.0) 
    TZD + insulin 1 (4.3) 3 (12.5) 2 (8.3) 
Total daily insulin dose 90.0 (70.0–136.0) 93.0 (67.5–136.0) 84.5 (58.0–135.5) 
A1C (%) 8.4 ± 0.9 8.4 ± 0.7 8.5 ± 0.9 
FPG (mg/dl) 165.9 ± 51.5 156.0 ± 39.0 161.6 ± 55.0 

Data are means ± SD, n (%), or median (interquartile range).

*Ethnicity data were collected for sites in the U.S. only.

†Before 50% insulin dose reduction on day 1 of double-blind period.

Efficacy outcomes

Figure 2 shows A1C, FPG, and change from baseline in body weight over time. In the 10- and 20-mg dapagliflozin groups, A1C decreased from baseline to week 12 (LOCF), resulting in differences in mean changes versus placebo of −0.70 and −0.78% (Table 2). At week 12 (LOCF), 65.2% of patients in both dapagliflozin groups achieved a ≥0.5% decrease from baseline A1C versus 15.8% in the placebo group. Five patients (one each in the dapagliflozin 20-mg and placebo groups, and three in the dapagliflozin 10-mg group) showed a therapeutic response defined as A1C <7%. At week 12 (LOCF), mean changes in total body weight were −1.9 kg (placebo), −4.5 kg (10 mg dapagliflozin), and −4.3 kg (20 mg dapagliflozin).

Figure 2

Mean A1C (A), mean FPG (B), and mean change from baseline in total body weight (C) over time. Data are for randomly assigned patients who took at least one dose of the double-blind study medication. Shown are mean values based on LOCF, excluding data after up-titration of insulin. Error bars represent 95% CIs. DAPA, dapagliflozin; INS, insulin; PLA, placebo.

Figure 2

Mean A1C (A), mean FPG (B), and mean change from baseline in total body weight (C) over time. Data are for randomly assigned patients who took at least one dose of the double-blind study medication. Shown are mean values based on LOCF, excluding data after up-titration of insulin. Error bars represent 95% CIs. DAPA, dapagliflozin; INS, insulin; PLA, placebo.

Close modal
Table 2

Baseline, with treatment, and change from baseline in efficacy parameters for randomly assigned patients in the treatment cohort

nBaseline*Week 12 (LOCF)*Change from baseline and differences in change vs. placebo + insulin*
A1C (%)     
    Placebo + insulin 19 8.3 ± 0.8 8.5 ± 0.8 0.09 (−0.2 to 0.4) 
    10 mg dapagliflozin+ insulin 23 8.4 ± 0.7 7.8 ± 0.7 −0.61 (−0.9 to −0.4) 
    Difference in change vs. placebo + insulin    −0.70 (−1.1 to −0.3) 
    20 mg dapagliflozin+ insulin 23 8.5 ± 0.9 7.8 ± 0.6 −0.69 (−0.9 to −0.4) 
    Difference in change vs. placebo + insulin    −0.78 (−1.2 to −0.4) 
FPG (mg/dl)     
    Placebo + insulin 22 166.8 ± 52.6 180.8 ± 56.9 17.8 (1.4 to 34.2) 
    10 mg dapagliflozin + insulin 23 155.7 ± 39.8 160.5 ± 38.7 2.4 (−13.6 to 18.3) 
    Difference in change vs. placebo + insulin    −15.4 (−38.4 to 7.5) 
    20 mg dapagliflozin + insulin 23 157.9 ± 53.0 149.4 ± 32.0 −9.6 (−25.6 to 6.3) 
    Difference in change vs. placebo + insulin    −27.4 (−50.3 to −4.6) 
Body weight (kg)     
Placebo + insulin 22 101.3 ± 16.7 99.4 ± 16.7 −1.9 (−2.9 to −0.9) 
10 mg dapagliflozin + insulin 23 102.8 ± 9.9 98.2 ± 9.4 −4.5 (−5.5 to −3.5) 
Difference in change vs. placebo + insulin    −2.6 (−4.0 to −1.2) 
20 mg dapagliflozin + insulin 23 102.1 ± 15.0 97.8 ± 14.1 −4.3 (−5.3 to −3.3) 
Difference in change vs. placebo + insulin    −2.4 (−3.8 to −1.0) 
TDDI (units)     
    Placebo + insulin 22 54.1 ± 27.3 55.7 ± 26.5 1.7 (−3.8 to 7.2) 
    10 mg dapagliflozin + insulin 24 52.4 ± 24.4 51.3 ± 20.1 −1.4 (−6.6 to 3.9) 
    Difference in change vs. placebo + insulin    −3.1 (−10.7 to 4.6) 
    20 mg dapagliflozin + insulin 24 54.5 ± 36.3 53.5 ± 32.1 −0.8 (−6.1 to 4.5) 
    Difference in change vs. placebo + insulin    −2.5 (−10.2 to 5.1) 
PPG (mg/dl)     
    Placebo + insulin 15 312.6 ± 82.2 331.3 ± 46.8 18.7 (−13.5 to 50.9) 
    10 mg dapagliflozin + insulin 19 320.2 ± 51.4 286.0 ± 55.1 −34.3 (−67.5 to −1.1) 
    20 mg dapagliflozin + insulin 18 314.5 ± 71.8 272.6 ± 51.2 −41.9 (−74.8 to −8.9) 
nBaseline*Week 12 (LOCF)*Change from baseline and differences in change vs. placebo + insulin*
A1C (%)     
    Placebo + insulin 19 8.3 ± 0.8 8.5 ± 0.8 0.09 (−0.2 to 0.4) 
    10 mg dapagliflozin+ insulin 23 8.4 ± 0.7 7.8 ± 0.7 −0.61 (−0.9 to −0.4) 
    Difference in change vs. placebo + insulin    −0.70 (−1.1 to −0.3) 
    20 mg dapagliflozin+ insulin 23 8.5 ± 0.9 7.8 ± 0.6 −0.69 (−0.9 to −0.4) 
    Difference in change vs. placebo + insulin    −0.78 (−1.2 to −0.4) 
FPG (mg/dl)     
    Placebo + insulin 22 166.8 ± 52.6 180.8 ± 56.9 17.8 (1.4 to 34.2) 
    10 mg dapagliflozin + insulin 23 155.7 ± 39.8 160.5 ± 38.7 2.4 (−13.6 to 18.3) 
    Difference in change vs. placebo + insulin    −15.4 (−38.4 to 7.5) 
    20 mg dapagliflozin + insulin 23 157.9 ± 53.0 149.4 ± 32.0 −9.6 (−25.6 to 6.3) 
    Difference in change vs. placebo + insulin    −27.4 (−50.3 to −4.6) 
Body weight (kg)     
Placebo + insulin 22 101.3 ± 16.7 99.4 ± 16.7 −1.9 (−2.9 to −0.9) 
10 mg dapagliflozin + insulin 23 102.8 ± 9.9 98.2 ± 9.4 −4.5 (−5.5 to −3.5) 
Difference in change vs. placebo + insulin    −2.6 (−4.0 to −1.2) 
20 mg dapagliflozin + insulin 23 102.1 ± 15.0 97.8 ± 14.1 −4.3 (−5.3 to −3.3) 
Difference in change vs. placebo + insulin    −2.4 (−3.8 to −1.0) 
TDDI (units)     
    Placebo + insulin 22 54.1 ± 27.3 55.7 ± 26.5 1.7 (−3.8 to 7.2) 
    10 mg dapagliflozin + insulin 24 52.4 ± 24.4 51.3 ± 20.1 −1.4 (−6.6 to 3.9) 
    Difference in change vs. placebo + insulin    −3.1 (−10.7 to 4.6) 
    20 mg dapagliflozin + insulin 24 54.5 ± 36.3 53.5 ± 32.1 −0.8 (−6.1 to 4.5) 
    Difference in change vs. placebo + insulin    −2.5 (−10.2 to 5.1) 
PPG (mg/dl)     
    Placebo + insulin 15 312.6 ± 82.2 331.3 ± 46.8 18.7 (−13.5 to 50.9) 
    10 mg dapagliflozin + insulin 19 320.2 ± 51.4 286.0 ± 55.1 −34.3 (−67.5 to −1.1) 
    20 mg dapagliflozin + insulin 18 314.5 ± 71.8 272.6 ± 51.2 −41.9 (−74.8 to −8.9) 

Data are means ± SD or mean (95% CI). n = 71.

*Excludes data after insulin up-titration, except for TDDI.

†Adjusted change from baseline based on an ANCOVA model with treatment group as an effect and baseline value as a covariate.

‡Number of subjects with a nonmissing baseline and a week 12 LOCF value.

The effect of dapagliflozin on FPG was dose dependent. PPG, measured at 120 min by an oral glucose tolerance test, also showed dose-response characteristics. There was no appreciable change from baseline in TDDI. Four patients in the placebo arm required insulin up-titration, compared with one in the dapagliflozin 10-mg arm and three in the dapagliflozin 20-mg arm.

Vital signs and laboratory outcomes

The placebo group experienced a slight increase in standing blood pressure at week 12, whereas both dapagliflozin groups demonstrated mean improvements in standing systolic and diastolic blood pressure (−7.2 systolic/–1.2 diastolic mmHg [10 mg dapagliflozin] and −6.1 systolic/–3.9 diastolic mmHg [20 mg dapagliflozin]). In the 20-mg dapagliflozin group, supine blood pressure decreased (mean change of −5.5 mmHg systolic/–5.8 mmHg diastolic), whereas there was little or no change in the 10-mg group (supplementary Table 1, available in the online appendix).

Mean changes from baseline in urinary glucose excretion at week 12 were −1.5 g/24 h (placebo), 83.5 g/24 h (10 mg dapagliflozin), and 85.2 g/24 h (20 mg dapagliflozin). Mean 24-h urine output increased from 1,870 to 2,125 ml (placebo), from 1,921 to 2,286 ml (10 mg dapagliflozin), and from 1,809 to 2,253 ml (20 mg dapagliflozin). Compared with baseline, Modification of Diet in Renal Disease–estimated glomerular filtration rates at the end of treatment were normal, with minor changes of −0.58, −0.84, and 1.45 ml/min per 1.73 m2 in the respective placebo and 10- and 20-mg dapagliflozin groups. Generally, there were no remarkable changes from baseline in key laboratory parameters. Median change from baseline in serum uric acid was −0.30 mg/dl in both dapagliflozin groups. There were no marked abnormalities for serum Na+ and liver function tests. Median increases from baseline in serum hematocrit at week 12 were 2.5 and 3.05% in the 10- and 20-mg dapagliflozin groups, respectively.

Safety and adverse events

Adverse events were balanced across all groups (Table 3). Three patients who received placebo, seven who received 10 mg dapagliflozin, and six who received 20 mg dapagliflozin experienced episodes of hypoglycemia. Of these, one patient who received placebo experienced major hypoglycemia. There were no deaths. Two patients, one in the placebo and one in the 20-mg dapagliflozin group, experienced a serious adverse event. One patient in each treatment arm experienced an adverse event that led to discontinuation.

Table 3

Adverse and special interest events, double-blind treatment period for patients in the treatment cohort

Placebo + insulin10 mg dapagliflozin + insulin20 mg dapagliflozin + insulin
n 23 24 24 
Overall adverse events*    
    At least one adverse event 15 (65.2) 18 (75.0) 16 (66.7) 
    At least one serious adverse event 1 (4.3)  1 (4.2) 
    Adverse event leading to discontinuation of study medication 1 (4.3)§ 1 (4.2) 1 (4.2) 
Most common adverse events (frequency >5% in any treatment group)    
    Nausea 1 (4.3) 1 (4.2) 3 (12.5) 
    Pollakiuria 4 (17.4) 2 (8.3) 3 (12.5) 
    Vomiting   3 (12.5) 
    Vulvovaginal mycotic infection   3 (12.5) 
    Anxiety   2 (8.3) 
    Back pain 2 (8.7) 3 (12.5) 2 (8.3) 
    Dry mouth   2 (8.3) 
    Nasopharyngitis 2 (8.7) 2 (8.3) 2 (8.3) 
    Edema, peripheral   2 (8.3) 
    Abdominal pain, upper 2 (8.7)  1 (4.2) 
    Fatigue  2 (8.3) 1 (4.2) 
    Influenza 2 (8.7) 1 (4.2) 1 (4.2) 
    Pain in extremity 1 (4.3) 2 (8.3) 1 (4.2) 
    Thirst 1 (4.3) 2 (8.3) 1 (4.2) 
    Upper respiratory tract infection 2 (8.7) 2 (8.3) 1 (4.2) 
    Headache 2 (8.7) 3 (12.5)  
    Pharyngolaryngeal pain  2 (8.3)  
    Procedural pain 2 (8.7)   
Adverse events of special interest    
    Urinary tract infection   1 (4.2) 
    Genital tract infection (total patients with an event) 1 (4.3)  5 (20.8) 
    Vulvovaginal mycotic infection   3 (12.5) 
    Balanitis candida   1 (4.2) 
    Vaginal candidiasis   1 (4.2) 
    Genital infection, fungal 1 (4.3)   
Events of hypoglycemia    
    Total patients with hypoglycemia 3 (13.0) 7 (29.2) 6 (25.0) 
        Major episode of hypoglycemia# 1 (4.3)   
Discontinuation due to lack of glycemic control    
    Overall 2 (8.7) 1 (4.2)  
    Before up-titration of insulin 1 (4.3)   
    On or after day of up-titration of insulin 1 (4.3) 1 (4.2)  
Placebo + insulin10 mg dapagliflozin + insulin20 mg dapagliflozin + insulin
n 23 24 24 
Overall adverse events*    
    At least one adverse event 15 (65.2) 18 (75.0) 16 (66.7) 
    At least one serious adverse event 1 (4.3)  1 (4.2) 
    Adverse event leading to discontinuation of study medication 1 (4.3)§ 1 (4.2) 1 (4.2) 
Most common adverse events (frequency >5% in any treatment group)    
    Nausea 1 (4.3) 1 (4.2) 3 (12.5) 
    Pollakiuria 4 (17.4) 2 (8.3) 3 (12.5) 
    Vomiting   3 (12.5) 
    Vulvovaginal mycotic infection   3 (12.5) 
    Anxiety   2 (8.3) 
    Back pain 2 (8.7) 3 (12.5) 2 (8.3) 
    Dry mouth   2 (8.3) 
    Nasopharyngitis 2 (8.7) 2 (8.3) 2 (8.3) 
    Edema, peripheral   2 (8.3) 
    Abdominal pain, upper 2 (8.7)  1 (4.2) 
    Fatigue  2 (8.3) 1 (4.2) 
    Influenza 2 (8.7) 1 (4.2) 1 (4.2) 
    Pain in extremity 1 (4.3) 2 (8.3) 1 (4.2) 
    Thirst 1 (4.3) 2 (8.3) 1 (4.2) 
    Upper respiratory tract infection 2 (8.7) 2 (8.3) 1 (4.2) 
    Headache 2 (8.7) 3 (12.5)  
    Pharyngolaryngeal pain  2 (8.3)  
    Procedural pain 2 (8.7)   
Adverse events of special interest    
    Urinary tract infection   1 (4.2) 
    Genital tract infection (total patients with an event) 1 (4.3)  5 (20.8) 
    Vulvovaginal mycotic infection   3 (12.5) 
    Balanitis candida   1 (4.2) 
    Vaginal candidiasis   1 (4.2) 
    Genital infection, fungal 1 (4.3)   
Events of hypoglycemia    
    Total patients with hypoglycemia 3 (13.0) 7 (29.2) 6 (25.0) 
        Major episode of hypoglycemia# 1 (4.3)   
Discontinuation due to lack of glycemic control    
    Overall 2 (8.7) 1 (4.2)  
    Before up-titration of insulin 1 (4.3)   
    On or after day of up-titration of insulin 1 (4.3) 1 (4.2)  

Data are n (%).

*Events of hypoglycemia were evaluated separately from adverse events.

†Loss of consciousness.

‡Noncardiac chest pain.

§Blood creatine phosphokinase increased

‖Renal failure. Other adverse events reported when patient was “discontinued” included increased blood creatinine, increased blood urea, dehydration, and dizziness

¶Microalbuminuria.

#Major hypoglycemic episode defined as 1) plasma blood glucose value <54 mg/dl, 2) at least one of the following symptoms: confusion/disorientation, abnormal behavior, or unconsciousness, and 3) external treatment provided.

Six patients experienced genital tract infections during the double-blind period; five of these received 20 mg dapagliflozin. One patient in the 20-mg dapagliflozin group reported a urinary tract infection. Events of pollakiuria were reported across all treatment groups, including the placebo group. One patient in each dapagliflozin arm reported polyuria. One case of microalbuminuria in the 20-mg dapagliflozin arm resulted in discontinuation.

One event of renal failure occurred during treatment with 10 mg dapagliflozin. The patient was being chronically treated with multiple antihypertensive agents, including enalapril, carvedilol, and furosemide. Eleven days after starting study medication, the patient was discontinued from the study because of dehydration and prerenal azotemia. Furosemide and enalapril therapy were withheld, and the prerenal azotemia resolved with oral rehydration.

Disease progression in type 2 diabetes is frequently accompanied by a cycle of deteriorating glycemic control due to declining β-cell function. Therapies that depend on insulin supplementation or secretion entail the risk of hypoglycemia, weight gain, decreased insulin sensitivity, and eventual loss of effectiveness. This frustrating clinical setting is exemplified most dramatically by patients with late-stage type 2 diabetes who require escalating insulin doses, often with oral agents such as metformin and/or TZDs to maintain glycemic control. Ultimately, > 25% of patients are treated with insulin-based regimens, often in combination with OADs (6). A novel strategy for controlling glycemia independently of insulin involves limiting glucose reabsorption in the proximal tubule of the kidney, where glucose is reabsorbed via SGLT2 receptors. Dapagliflozin selectively inhibits SGLT2, thereby limiting glucose reabsorption.

Patients recruited for this study had inadequate glycemic control despite aggressive regimens of insulin plus OADs. After reducing the insulin dose by 50%, patients in the placebo arm experienced weight loss, little change in A1C, and a mean 17.8 mg/dl increase in FPG, an outcome that probably reflects the relatively severe insulin resistance in these patients and perhaps improved compliance with diet and lifestyle as a result of study participation. Treatment with dapagliflozin, with its insulin-independent mechanism of action, was associated with additional weight loss of ∼2.5 kg and with improvements in glycemic control compared with placebo. Although the total number of hypoglycemic events reported was greater with dapagliflozin than with placebo, there were no major hypoglycemia episodes with dapagliflozin. The effect of dapagliflozin in this insulin-treated population was similar to that observed in treatment-naive diabetic patients (19).

Improvements in glycemic outcome measures were dose dependent, as was the potential safety signal of genital tract infections, more frequently seen in the 20-mg dapagliflozin dose arm. However, the main pharmacodynamic measure, 24-h urinary glucose, increased by ∼85 g/day at week 12 in both the 10-mg and 20-mg dapagliflozin groups. A plausible explanation is that 20 mg dapagliflozin may have caused greater glucosuria earlier in the study, as has been seen in other settings (18,20), but that the resulting greater declines in glycemia in the 20-mg dose group led to a lower filtered load of glucose at the kidney, such that by week 12, the point at which glucosuria was measured, the amount of glucose in the urine had equalized between the dapagliflozin dose groups.

Reductions in standing blood pressure in both dapagliflozin groups and in supine blood pressure in the dapagliflozin 20-mg group are noteworthy. The decrease in blood pressure and slight increase in hematocrit are effects consistent with the glucose-induced osmotic diuresis caused by SGLT2 inhibition. A dramatic presentation of this effect was seen in the 10-mg dose arm in an event of dehydration and prerenal azotemia in a volume-sensitive patient. Otherwise, there were no further reports of dizziness or dehydration associated with dapagliflozin in this study. The diuretic property of dapagliflozin warrants further evaluation.

Conclusions that can be drawn from this study are limited by its size and relatively short duration. Nevertheless, these results establish the proof of concept that SGLT2 inhibition can improve glycemic control and weight in patients with diabetes that is poorly controlled with high insulin doses and oral insulin sensitizer therapy, despite a 50% insulin dose reduction. These results further suggest the hypothesis that this therapeutic approach may lend itself to reducing the weight gain that otherwise might occur when insulin therapy is intensified in this population.

Clinical trial reg. no. NCT00357370, clinicaltrials.gov.

A complete list of investigators can be found in an online appendix, available at http://care.diabetesjournals.org/cgi/content/full/dc09-0517/DC1.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This study was funded by Bristol-Myers Squibb and AstraZeneca. J.P.H.W. has received consultancy fees from Bristol-Myers Squibb and AstraZeneca, codevelopers of dapagliflozin; has served on a scientific advisory panel for Bristol-Myers Squibb and AstraZeneca; has received research support and lecture fees from AstraZeneca; and is an investigator for ongoing clinical trials with dapagliflozin. P.N. was a trialist for this study and has performed clinical trials funded by Bristol-Myers Squibb. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.

We thank Paul Strumph and Stephanie Moran for their substantial contributions in developing the study design and protocol; Maryse Courval and Dominique Duchesne for their assistance as protocol managers; and the investigators and contributors from each of the study sites. We also thank Alan G. Hempel, Bristol-Myers Squibb, for writing and editorial support, and William Watkins, PAREXEL, for editorial and graphics support.

1
Turner
RC
,
Cull
CA
,
Frighi
V
,
Holman
RR
.
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group
.
JAMA
1999
; 
281
:
2005
2012
2
Holman
RR
,
Thorne
KI
,
Farmer
AJ
,
Davies
MJ
,
Keenan
JF
,
Paul
S
,
Levy
JC
4-T Study Group.
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
.
N Engl J Med
2007
; 
357
:
1716
1730
3
Poulsen
MK
,
Henriksen
JE
,
Hother-Nielsen
O
,
Beck-Nielsen
H
.
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients
.
Diabetes Care
2003
; 
26
:
3273
3279
4
Wright
A
,
Burden
AC
,
Paisey
RB
,
Cull
CA
,
Holman
RR
.
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)
.
Diabetes Care
2002
; 
25
:
330
336
5
Holman
RR
,
Paul
SK
,
Bethel
MA
,
Matthews
DR
,
Neil
HA
.
10-year follow-up of intensive glucose control in type 2 diabetes
.
N Engl J Med
2008
; 
359
:
1577
1589
6
Koro
CE
,
Bowlin
SJ
,
Bourgeois
N
,
Fedder
DO
.
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report
.
Diabetes Care
2004
; 
27
:
17
20
7
Yki-Jarvinen
H
.
Combination therapies with insulin in type 2 diabetes
.
Diabetes Care
2001
; 
24
:
758
767
8
Buse
J
.
Combining insulin and oral agents
.
Am J Med
2000
; 
108
(
Suppl. 6a
):
23S
32S
9
Wilding
J
.
Thiazolidinediones, insulin resistance and obesity: finding a balance
.
Int J Clin Pract
2006
; 
60
:
1272
1280
10
Makimattila
S
,
Nikkila
K
,
Yki-Jarvinen
H
.
Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus
.
Diabetologia
1999
; 
42
:
406
412
11
Nathan
DM
,
Buse
JB
,
Davidson
MB
,
Ferrannini
E
,
Holman
RR
,
Sherwin
R
,
Zinman
B
American Diabetes Association, European Association for the Study of Diabetes.
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
.
Diabetes Care
2009
; 
32
:
193
203
12
Kanai
Y
,
Lee
WS
,
You
G
,
Brown
D
,
Hediger
MA
.
The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for d-glucose
.
J Clin Invest
1994
; 
93
:
397
404
13
Brown
GK
.
Glucose transporters: structure, function and consequences of deficiency
.
J Inherit Metab Dis
2000
; 
23
:
237
246
14
Han
S
,
Hagan
DL
,
Taylor
JR
,
Xin
L
,
Meng
W
,
Biller
SA
,
Wetterau
JR
,
Washburn
WN
,
Whaley
JM
.
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
.
Diabetes
2008
; 
57
:
1723
1729
15
Adachi
T
,
Yasuda
K
,
Okamoto
Y
,
Shihara
N
,
Oku
A
,
Ueta
K
,
Kitamura
K
,
Saito
A
,
Iwakura
I
,
Yamada
Y
,
Yano
H
,
Seino
Y
,
Tsuda
K
.
T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
.
Metabolism
2000
; 
49
:
990
995
16
Katsuno
K
,
Fujimori
Y
,
Takemura
Y
,
Hiratochi
M
,
Itoh
F
,
Komatsu
Y
,
Fujikura
H
,
Isaji
M
.
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
.
J Pharmacol Exp Ther
2007
; 
320
:
323
330
17
Fujimori
Y
,
Katsuno
K
,
Nakashima
I
,
Ishikawa-Takemura
Y
,
Fujikura
H
,
Isaji
M
.
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
.
J Pharmacol Exp Ther
2008
; 
327
:
268
276
18
Komoroski
B
,
Vachharajani
N
,
Feng
Y
,
Li
L
,
Kornhauser
D
,
Pfister
M
.
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
.
Clin Pharmacol Ther
2009
; 
85
:
513
519
19
List
JF
,
Woo
V
,
Morales
E
,
Tang
W
,
Fiedorek
FT
.
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
.
Diabetes Care
2009
; 
32
:
650
657
20
Komoroski
B
,
Vachharajani
N
,
Boulton
D
,
Kornhauser
D
,
Geraldes
M
,
Li
L
,
Pfister
M
.
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects
.
Clin Pharmacol Ther
2009
; 
85
:
520
526

Supplementary data